At EBMT 2025, Dr. Giorgia Battipaglia shared important findings from a multicenter study comparing post-transplant cyclophosphamide (PTCy) versus antithymocyte globulin (ATG) as GVHD prophylaxis in patients with relapsed/refractory AML undergoing haploidentical HSCT. Both approaches were shown to be viable options. While ATG was linked to higher neutrophil engraftment and reduced incidence of chronic GVHD, no significant differences were observed in non-relapse mortality, relapse incidence, or overall survival between the groups. Further analysis is ongoing to clarify these results.
Thank you to Dr. Giorgia Battipaglia and the Acute Leukemia Working Party of the EBMT for advancing our understanding of transplant strategies.
For more details: https://lnkd.in/dWQ5ZfmG
